全球T細胞療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

T 細胞療法市場預計將從 2025 年的 54 億美元成長到 2034 年的 253.1 億美元，2026 年至 2034 年的複合年成長率為 18.72%。

由於免疫療法的突破性進展，全球T細胞療法市場正經歷快速成長。 T細胞療法，包括CAR-T療法，利用人體免疫系統標靶癌細胞。骨髓惡性腫瘤率的上升是推動市場擴張的主要因素。

關鍵成長要素包括臨床試驗數量的增加以及先進治療方法監管核准。製藥和生物技術公司正大力投資於以細胞為基礎的治療創新。人們對個人化醫療日益成長的興趣也進一步推動了需求。此外，已開發市場的支持性報銷機制也正在加速這些療法的普及。

隨著固態腫瘤應用研究的不斷深入，未來前景依然強勁。新興市場對先進醫療基礎設施的投資將創造新的機會。各公司正致力於提高生產擴充性並降低治療成本。隨著免疫療法的不斷發展，全球T細胞療法市場預計將迎來顯著的長期成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球T細胞療法市場：依治療方法類型分類

• 市場分析、洞察與預測
• CAR-T細胞療法
• 基於T細胞受體（TCR）

第5章 全球T細胞療法市場：依適應症分類

• 市場分析、洞察與預測
• 淋巴瘤
• 急性淋巴性白血病
• 其他

第6章 全球T細胞療法市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 癌症治療中心

第7章 全球T細胞療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Gilead Sciences Inc
  • Cellectis Inc
  • Johnson & Johnson
  • Celyad Oncology
  • Immunocore Ltd
  • Autolus Therapeutics
  • Novartis AG
  • Cartesian Therapeutics Inc
  • Caribou Biosciences Inc
  • Bristol-Myers Squibb Company

The T-Cell Therapies Market size is expected to reach USD 25.31 Billion in 2034 from USD 5.40 Billion (2025) growing at a CAGR of 18.72% during 2026-2034.

The Global T-Cell Therapies Market is experiencing rapid growth due to breakthroughs in immunotherapy. T-cell therapies, including CAR-T treatments, harness the immune system to target cancer cells. Rising prevalence of hematological malignancies is supporting market expansion.

Major growth drivers include increasing clinical trials and regulatory approvals for advanced therapies. Pharmaceutical and biotech companies are investing heavily in cell-based treatment innovation. Growing focus on personalized medicine is further strengthening demand. Additionally, supportive reimbursement frameworks in developed markets are encouraging adoption.

Future prospects remain strong as research expands into solid tumor applications. Emerging markets investing in advanced healthcare infrastructure will create new opportunities. Companies are focusing on scalable manufacturing and reduced treatment costs. As immunotherapy continues to evolve, the Global T-Cell Therapies Market is expected to witness substantial long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Therapy Type

• CAR T-Cell Therapy
• T-Cell Receptor (TCR)-Based

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By End User

• Hospitals
• Cancer Treatment Centers

COMPANIES PROFILED

• Gilead Sciences Inc, Cellectis Inc, Johnson Johnson, Celyad Oncology, Immunocore Ltd, Autolus Therapeutics, Novartis AG, Cartesian Therapeutics Inc, Caribou Biosciences Inc, BristolMyers Squibb Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL T-CELL THERAPIES MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. CAR T-Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. T-Cell Receptor (TCR)-Based Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL T-CELL THERAPIES MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Acute Lymphocytic Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL T-CELL THERAPIES MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Cancer Treatment Centers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL T-CELL THERAPIES MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Type
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Type
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Type
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Type
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Type
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL T-CELL THERAPIES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Gilead Sciences Inc
  • 9.2.2 Cellectis Inc
  • 9.2.3 Johnson & Johnson
  • 9.2.4 Celyad Oncology
  • 9.2.5 Immunocore Ltd
  • 9.2.6 Autolus Therapeutics
  • 9.2.7 Novartis AG
  • 9.2.8 Cartesian Therapeutics Inc
  • 9.2.9 Caribou Biosciences Inc
  • 9.2.10 Bristol-Myers Squibb Company